Effect of rituximab combined with chemotherapy on CRP and TNF-α levels in patients with diffuse large B-cell lymphoma
Objective To explore the effect of rituximab combined with chemotherapy on C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)levels in patients with diffuse large B-cell lymphoma(DLBCL).Methods 92 patients with diffuse large B-cell lymphoma were divided into a control group and an observation group,with 46 cases in each group.The control group was treated with chemotherapy alone,and the observation group was treated with rituximab and chemotherapy.The clinical efficacy,occurrence of adverse reactions,test indicators[CRP,TNF-α,carbohydrate antigen 125(CA125)],quality of life,immune function(CD3+,CD4+,CD8+ and CD4+/CD8+)of the two groups were compared.Results The total effective rate of the observation group was 71.74%,which was higher than 50.00%of the control group(P<0.05).After treatment,the observation group had CRP of(4.01±2.36)mg/L,TNF-α of(18.54±8.32)pg/ml,CA125 of(26.41±2.25)U/ml,which were lower than(6.25±2.36)mg/L,(26.93±7.25)pg/ml and(34.21±3.58)U/ml in the control group(P<0.05).The incidence of adverse reactions was 21.74%in the observation group,and there was no statistically significant difference compared to the control group's 30.43%(P>0.05).After treatment,the Karnofsky performance scale(KPS)score of(83.79±7.84)points in the observation group was higher than(73.78±6.89)points in the control group,and Zubrod-ECOG-WHO(ZPS)score of(0.93±0.27)points was lower than(1.43±0.31)points in the control group(P<0.05).After treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than that in the control group(P<0.05).Conclusion For patients with diffuse large B-cell lymphoma,rituximab combined with chemotherapy can achieve more significant efficacy,promote the reduction of CRP,TNF-α and CA125 levels,protect the immune function of patients,and have a high drug safety,which can be promoted and used in clinical practice.
RituximabChemotherapyDiffuse large B-cell lymphomaInflammatory factors
NETL
NSTL
万方数据
